"Ifosfamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
| Descriptor ID |
D007069
|
| MeSH Number(s) |
D02.455.526.728.650.730.243.250 D02.705.672.500.243.250 D03.383.533.500
|
| Concept/Terms |
Ifosfamide- Ifosfamide
- Isofosfamide
- Isophosphamide
- Iphosphamide
- Iso-Endoxan
- Iso Endoxan
NSC-109,724- NSC-109,724
- NSC 109,724
- NSC109,724
- NSC-109724
- NSC 109724
- NSC109724
|
Below are MeSH descriptors whose meaning is more general than "Ifosfamide".
Below are MeSH descriptors whose meaning is more specific than "Ifosfamide".
This graph shows the total number of publications written about "Ifosfamide" by people in this website by year, and whether "Ifosfamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 3 | 2 | 5 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 3 | 3 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ifosfamide" by people in Profiles.
-
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
-
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Cancer. 2016 Feb 15; 122(4):559-64.
-
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leuk Res. 2015 Dec; 39(12):1437-42.
-
Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms. Drug Metab Dispos. 2015 Jul; 43(7):1084-90.
-
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Ann Oncol. 2013 Dec; 24(12):3076-81.
-
Moyamoya in a child treated with interferon for recurrent osteosarcoma. J Pediatr Hematol Oncol. 2010 Aug; 32(6):476-8.
-
Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1147-53.
-
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. Cancer. 2008 Jun; 112(11):2432-9.
-
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair (Amst). 2007 Aug 01; 6(8):1145-54.
-
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Pediatr Blood Cancer. 2004 Oct; 43(5):571-9.